They are compounded by licensed 503A pharmacies with physician oversight and sterile quality standards, prioritizing real therapeutic outcomes over cheaper, unregulated research-grade products
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
KLOW and its component peptides are research-use-only materials, are not FDA-approved, and are not intended for human consumption
Case reports of Melanotan II describe patients developing darkening of pre-existing moles and oral mucosa, priapism requiring emergency intervention, injection-site ulceration and pyoderma gangrenosum , renal infarction , and even a possible association with reports of ischemic strokeafter intranasal use